Diagnosis and Treatment of Antiphospholipid Syndrome During Pregnancy
For pregnant women with APS, treat with low-dose aspirin (LDA) plus low molecular weight heparin (LMWH) starting immediately after pregnancy confirmation—this combination is superior to aspirin alone and reduces adverse pregnancy outcomes by approximately 7.5-fold compared to no treatment 1, 2.
Diagnostic Approach
Laboratory Testing Requirements
Diagnose APS by detecting persistent antiphospholipid antibodies on two separate occasions at least 12 weeks apart 3, 4:
- Lupus anticoagulant (LA) - Most predictive for pregnancy morbidity, especially when combined with anti-β2GPI 3
- Anticardiolipin antibodies (aCL) - IgG or IgM, medium-to-high titers
- Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG or IgM, medium-to-high titers
Critical caveat: aPL levels fluctuate during pregnancy. LA may become falsely negative in 25% of patients during second/third trimester due to rising Factor VIII levels that shorten APTT 3. IgG aCL and aβ2GPI remain positive in 93% and 85% respectively throughout pregnancy 3.
Risk Stratification by Antibody Profile
Triple-positive patients (LA + aCL + aβ2GPI) carry the highest risk—90% present with clinical APS criteria 3. Double-positive with concordant isotype (LA negative but aCL and aβ2GPI positive of same isotype) also represents high-risk profile 3. Isolated LA remains strongly predictive for adverse pregnancy outcomes despite debate 3.
Clinical Criteria for Obstetric APS
Requires one or more of the following with persistent aPL:
- Three or more consecutive spontaneous miscarriages before 10 weeks
- One or more unexplained fetal deaths ≥10 weeks gestation
- One or more premature births <34 weeks due to severe preeclampsia, eclampsia, or placental insufficiency
Treatment Protocol
Preconception Phase
Start low-dose aspirin (75-100 mg daily) before attempting conception 1, 5.
After Pregnancy Confirmation
Immediately add LMWH to aspirin 1, 2. The combination of aspirin plus LMWH shows 13.2-fold higher odds of live birth compared to aspirin alone 2.
Dosing regimens:
- Prophylactic LMWH (enoxaparin 40 mg daily or dalteparin 5000 units daily) for obstetric APS
- Therapeutic LMWH doses for patients with prior thrombosis (vascular APS)
Special Populations
Patients with systemic lupus erythematosus (SLE): Add hydroxychloroquine preconceptionally and throughout pregnancy 1. SLE significantly increases risk for preterm birth and preeclampsia 2. These patients require more intensive monitoring.
Patients with prior thrombosis: Continue therapeutic anticoagulation throughout pregnancy. Switch from warfarin to LMWH immediately upon positive pregnancy test 5.
Monitoring During Pregnancy
Implement supplementary fetal surveillance 1:
- Doppler ultrasonography in third trimester for placental insufficiency
- Serial biometric parameters to detect small-for-gestational-age fetuses
- Monitor renal function and serological markers (C3/C4, anti-dsDNA) for disease flares 1
Watch for thrombotic microangiopathy: APS may present as life-threatening TMA mimicking severe preeclampsia but requiring different treatment 6.
Postpartum Management
Restart warfarin 4-6 hours after vaginal delivery or 6-12 hours after cesarean delivery for patients requiring long-term anticoagulation 5. Continue prophylactic anticoagulation for 6 weeks postpartum in all APS patients due to high thrombotic risk.
Refractory Cases
Despite standard treatment, 30% of women with definite APS experience adverse pregnancy outcomes 6, 4. LA-positive patients face at least 30% likelihood of complications even with treatment 6.
For refractory cases, consider:
- Intravenous immunoglobulin (IVIG)
- Increased glucocorticoid doses
- Plasmapheresis 1
These remain controversial with limited evidence but may be attempted in severe refractory disease.
Seronegative or Non-Criteria APS
Patients with recurrent early miscarriage without preeclampsia/placental insufficiency or those with only low-titer antibodies or isolated IgM isotype do not meet current classification criteria 6. For these patients, consider empiric treatment with LDA alone or LDA plus LMWH based on clinical judgment, as isolated aCL or aβ2GPI show poor association with thrombosis 3.
Key Pitfalls to Avoid
- Do not use direct oral anticoagulants (DOACs) during pregnancy—insufficient safety data 7
- Do not rely on single positive aPL test—requires confirmation at ≥12 weeks 3
- Do not use combined hormonal contraceptives in aPL-positive women due to thrombotic risk 1
- Do not delay LMWH initiation after pregnancy confirmation—early treatment is critical 2